High-resolution analytical platforms from Agilent Technologies will be made available through C-CAMP’s shared infrastructure model under expanded collaboration
The global JAK inhibitors market is projected to REACH $56.78 billion by 2030, reflecting strong demand for targeted immunology treatments
Shashwat Goenka takes over as Vice President of industry body
The two companies will establish a joint Center of Excellence (CoE) in Bengaluru
The clearance marks a pivotal step forward for the company as it pushes deeper into AI-driven diagnostics and expands its clinical footprint in point-of-care imaging
Investment will support LifeSigns’ global expansion across Southeast Asia and GCC markets
Healthcare leaders, policymakers, hospitals, and patient advocates discuss AI-driven healthcare, digital transformation, quality of life in cancer care
India’s institutions now need to upgrade TTOs as strategic innovation units rather than administrative support cells
The once-daily oral therapy is the first and only tyrosine kinase 2 (TYK2) inhibitor approved in the European Union for this indication, marking a significant expansion of its immunology portfolio
Subscribe To Our Newsletter & Stay Updated
